{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:49:53Z","timestamp":1792147793370,"version":"4.4.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CDT"],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>The Apolipoprotein L (APOL) family, particularly APOL1, APOL2, and\nAPOL4, has been implicated in the pathogenesis of kidney injury, neuroinflammation, and several\npsychiatric disorders. However, there are currently no approved drugs available that can directly\ntarget these proteins, except for some APOL1-directed therapeutics. Identifying compounds that can\nmodulate multiple APOL paralogs may therefore offer a promising therapeutic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this study, a structure-based drug repurposing approach integrating molecular docking\nand MD simulations was employed to identify potential inhibitors of three APOL proteins. A library\nof 1,040 FDA-approved compounds was screened against APOL1, APOL2, and APOL4, followed\nby MD simulations to evaluate the stability and affinity of the identified complexes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>results:<\/jats:title>\n                    <jats:p>Docking analysis identified lopinavir and ritonavir as the only compounds meeting binding and stability criteria across all three APOL proteins. Both drugs demonstrated stable binding modes and favorable interaction energies during MD simulations. Ritonavir showed comparatively lower RMSD values and more confined conformational sampling, indicating enhanced structural stability. MM\/GBSA calculations confirmed negative binding free energies for all complexes, with APOL4\u2013ritonavir exhibiting the most favorable binding profile. ADMET analysis supported acceptable pharmacokinetic properties consistent with their approved clinical use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Docking analysis identified the antiviral drugs lopinavir and ritonavir as top-ranked potential\ninhibitors across all three APOL proteins. Ritonavir showed the strongest predicted binding affinity\ntoward APOL1 (-10.46 kcal\/mol) and APOL2 (-9.66 kcal\/mol), while lopinavir exhibited the\nhighest affinity for APOL4 (-9.21 kcal\/mol). Subsequent MD simulations combined with RMSD,\nRMSF, RoG, hydrogen-bond, PCA, DCCM, and FEL analyses provided computational support for\nthe persistence of the predicted protein-ligand interactions. MM\/GBSA calculations further supported\nfavorable predicted binding, with total energies ranging from -42.97 to -65.55 kcal\/mol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The identification of predicted shared inhibitors for APOL1, APOL2, and APOL4 is\nbiologically significant due to their conserved structural features and overlapping pathological pathways.\nRepurposing clinically approved antivirals with established clinical use may provide a starting\npoint for further investigation of APOL-targeting strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study provides the first computational evidence supporting cross-paralog APOL\ninhibition by repurposed antiviral drugs. These findings provide a computational basis for the development\nof APOL-targeted therapeutic strategies and warrant further experimental validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113894501494052261006091856","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:25:31Z","timestamp":1792146331000},"source":"Crossref","is-referenced-by-count":0,"title":["Computational Drug Repurposing Reveals Lopinavir and Ritonavir as Potential Inhibitors of APOL Proteins for Combating Kidney and\nNeuropsychiatric Disorders"],"prefix":"10.2174","volume":"27","author":[{"given":"Muhammad Ali","family":"Raza","sequence":"first","affiliation":[{"name":"State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, 100029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneer","family":"Ahmad","sequence":"additional","affiliation":[{"name":"College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, 110819, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Cheng","sequence":"additional","affiliation":[{"name":"School of Marxism, Hefei University of Technology, Hefei, 230000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Waleed","family":"Iqbal","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, 100029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Zeeshan","family":"Haider","sequence":"additional","affiliation":[{"name":"International Joint Laboratory on Synthetic Biology and Biomass Biorefinery, Biofuels Institute, School of Emergency Management, School of the Environment and Safety Engineering, Jiangsu University, Zhenjiang, 212013, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Zohaib","family":"Nawaz","sequence":"additional","affiliation":[{"name":"International Joint Laboratory on Synthetic Biology and Biomass Biorefinery, Biofuels Institute, School of Emergency Management, School of the Environment and Safety Engineering, Jiangsu University, Zhenjiang, 212013, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Shen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, 100029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501494052261006091856","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/259484\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501494052261006091856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:25:32Z","timestamp":1792146332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/259484\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501494052261006091856","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,13]]}}}